PA
EWTX icon

Profund Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Profund Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Buy
9,164
+481
+6% +$16.6K 0.01% 683
2026
Q1 		$274K Sell
8,683
-3,142
-27% -$90.6K 0.01% 809
2025
Q4 		$293K Buy
11,825
+16
+0.1% +$321 0.01% 890
2025
Q3 		$192K Sell
11,809
-3,276
-22% -$46.5K 0.01% 992
2025
Q2 		$198K Sell
15,085
-602
-4% -$8.68K 0.01% 910
2025
Q1 		$345K Buy
15,687
+742
+5% +$19.5K 0.02% 610
2024
Q4 		$399K Sell
14,945
-300
-2% -$9.55K 0.01% 628
2024
Q3 		$407K Buy
15,245
+3,840
+34% +$76.4K 0.02% 625
2024
Q2 		$205K Buy
+11,405
New +$199K 0.01% 971

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Profund Advisors's EWTX Position: Q2 2026 in Review

Profund Advisors increased its Edgewise Therapeutics (EWTX) stake by 5.5% in Q2 2026, buying an estimated $16.6K and bringing the position to 9,164 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #683.

Profund Advisors first reported a position in EWTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $407K in Q3 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Profund Advisors held 9,164 shares of Edgewise Therapeutics worth $372K as of Q2 2026.
  • Profund Advisors bought 481 Edgewise Therapeutics shares in Q2 2026, an estimated $16.6K.
  • Edgewise Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #683 holding.
  • Profund Advisors first reported a position in Edgewise Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Profund Advisors's Edgewise Therapeutics position peaked at $407K in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.